Edition:
United States

Rexahn Pharmaceuticals Inc (RNN)

RNN on American Stock Exchange

0.45USD
24 Mar 2017
Change (% chg)

$0.02 (+3.57%)
Prev Close
$0.43
Open
$0.44
Day's High
$0.45
Day's Low
$0.42
Volume
2,248,744
Avg. Vol
3,089,048
52-wk High
$0.56
52-wk Low
$0.13

Latest Key Developments (Source: Significant Developments)

Rexahn Pharma's cash and investments totaled about $20.3 mln as of Dec 31, 2016
Monday, 27 Feb 2017 09:00am EST 

Rexahn Pharmaceuticals Inc : Rexahn Pharmaceuticals reports full year 2016 financial results and provides corporate update .Rexahn Pharmaceuticals Inc - Rexahn's cash and investments totaled approximately $20.3 million as of December 31, 2016.  Full Article

Rexahn Pharmaceuticals Q2 loss per share $0.01
Monday, 8 Aug 2016 09:00am EDT 

Rexahn Pharmaceuticals Inc : Rexahn Pharmaceuticals reports second quarter 2016 financial and operational results . Q2 loss per share $0.01 .Expects current cash, investments sufficient to fund co's cash flow requirements for activities into second half of 2017.  Full Article

Rexahn Pharma Q1 loss per share $0.02
Monday, 9 May 2016 09:00am EDT 

Rexahn Pharmaceuticals Inc : Expects cash investments as of march 31, 2016 will be sufficient to fund requirements for current activities into h2 2017 . Rexahn pharmaceuticals reports first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.02.  Full Article

Rexahn Pharmaceuticals announces new data for Supinoxin Showing Potent Tumor Growth Inhibition
Monday, 14 Dec 2015 09:00am EST 

Rexahn Pharmaceuticals Inc:Announced that it presented new preclinical data for its anti-cancer compound, Supinoxin (RX-5902).Results demonstrated oral administration of ascending weekly doses of supinoxin showed dose-dependent, potent tumor growth inhibition.  Full Article

Rexahn Pharmaceuticals, Inc announces $7 mln registered direct offering
Friday, 6 Nov 2015 09:00am EST 

Rexahn Pharmaceuticals, Inc:Announces $7.0 million registered direct offering.Says net proceeds of the offering will be used for further development of rexahn's lead clinical programs.Entered into agreement with institutional investor to purchase about 16.7 million shares of its common stock.  Full Article

Rexahn Pharmaceuticals Inc's president and chief operating officer to resign with effective on July 21 - Form 8-K
Friday, 17 Jul 2015 04:13pm EDT 

Rexahn Pharmaceuticals Inc:Says that on July 13, Rexahn Pharmaceuticals Inc, was notified by Rakesh Soni, the company's president and chief operating officer, that Soni will resign his employment with the company effective on July 21.  Full Article

Rexahn Pharmaceuticals Inc Announces the Appointment of Peter Brandt as Chairman of the Board
Monday, 22 Jun 2015 09:00am EDT 

Rexahn Pharmaceuticals Inc:Says appointment of Peter Brandt as Chairman of the Board. Dr. Chang Ahn, Rexahn's founder, will remain on the Board as Chairman Emeritus and will continue in his role as the company's Chief Scientist.  Full Article

More From Around the Web

BRIEF-Rexahn Pharma's cash and investments totaled about $20.3 mln as of Dec 31, 2016

* Rexahn Pharmaceuticals reports full year 2016 financial results and provides corporate update